NF 340: Selective P2Y11 Antagonism for Advanced Cancer Pathway Research

Introduction: The Unexplored Potential of P2Y11 Antagonists in Cancer Research

The intersection of purinergic signaling and cancer biology presents a frontier for innovative research into cellular communication, metastasis, and immune modulation. While previous studies have profiled NF 340 (SKU B7508) as a potent and selective P2Y11 antagonist for cell signaling and immunology workflows, a rigorous mechanistic and translational analysis is still lacking. This article dissects the unique role of NF 340 in decoding P2Y11-driven pathways, moving beyond generic protocol optimization to reveal how targeted inhibition of this G protein-coupled receptor (GPCR) reframes our approach to cancer invasiveness and inflammation pathway modulation (workflow_recommendation).

Mechanism of Action of NF 340: Precision Targeting of P2Y11 Receptor

NF 340 (sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate) is a highly selective antagonist targeting the P2Y11 receptor, a member of the purinergic receptor family within the GPCR superfamily (product_spec). The P2Y11 receptor is distinguished by its dual coupling to Gq and Gs proteins, enabling it to modulate both intracellular calcium flux and cyclic AMP levels. By binding competitively to P2Y11, NF 340 blocks nucleotide-induced activation, thus inhibiting downstream signaling events such as phospholipase C activation, intracellular Ca²⁺ release, and cAMP accumulation (product_spec).

This mechanistic specificity is critical, as the P2Y11 receptor has been implicated in regulating immune cell migration, cytokine release, and—in the context of cancer—tumor cell motility and invasiveness (source: paper).

Reference Insight Extraction: QPRT, P2Y11, and Breast Cancer Invasiveness

Recent research by Liu et al. (2021) provides a crucial breakthrough in understanding how purinergic signaling, mediated by P2Y11, contributes to cancer cell invasiveness. The study demonstrated that overexpression of quinolinate phosphoribosyltransferase (QPRT)—the rate-limiting enzyme in the kynurenine pathway of NAD⁺ biosynthesis—increases breast cancer cell migration and invasion. Strikingly, the application of NF 340 reversed QPRT-induced invasiveness and suppressed myosin light chain phosphorylation, a key driver of cytoskeletal reorganization and cellular motility (source: paper).

This work establishes that QPRT-enhanced cancer progression is, at least in part, dependent on purinergic receptor signaling via P2Y11. For experimentalists, this means that NF 340 is not merely a generic cell signaling inhibitor, but a tool with validated utility for dissecting the metabolic and signaling crosstalk underlying metastatic phenotypes. This mechanistic linkage is not explored in existing scenario-driven or protocol-focused articles, which tend to emphasize technical performance or workflow Q&A rather than deep pathway biology.

Protocol Parameters

• assay | Storage temperature | -20°C | Ensures compound integrity and minimizes degradation | product_spec
• assay | Solution stability | Use immediately after preparation; not recommended for long-term storage | Preserves chemical activity and selectivity | product_spec
• assay | Working concentration | Not specified; recommend titration for cell-based assays (e.g., 0.1–10 µM) | Empirical optimization based on cell type and endpoint | workflow_recommendation
• assay | Solubility in water | <19.74 mg/ml | Guides solvent selection and maximum dosing | product_spec
• assay | Application | In vitro research only | Not suitable for diagnostic or therapeutic use | product_spec

Advanced Applications: NF 340 in Dissecting Inflammation and Cancer Pathways

Beyond its general role in GPCR signaling pathway studies, NF 340's selectivity for P2Y11 enables precise modulation of inflammation and immune response in both basic and translational research. The Liu et al. study established that interfering with P2Y11 disrupts the link between NAD⁺ metabolism and actomyosin contractility in cancer cells. This intersection is especially relevant for immunology research, where purinergic signaling orchestrates the recruitment and activation of leukocytes, as well as for studies on the inflammation pathway modulation in tumor microenvironments (source: paper).

For example, targeting P2Y11 with NF 340 can help unravel:

• How metabolic enzymes like QPRT modulate GPCR signaling in cancer and immune cells
• The role of purinergic receptor signaling in cytoskeletal dynamics and cancer cell motility
• Potential links between inflammation, NAD⁺ homeostasis, and tumor progression

Unlike prior articles that focus on validated performance in cell viability or reproducibility across workflows (see scenario-driven insights), this analysis foregrounds the mechanistic and translational implications of NF 340 in the context of cancer cell invasion and metabolic signaling—a distinct and advanced application niche.

Comparative Analysis: NF 340 Versus Alternative Approaches

While a range of P2Y receptor antagonists and GPCR inhibitors exist, NF 340’s unique selectivity for P2Y11 sets it apart for dissecting the specific purinergic pathways implicated in inflammation and cancer. Other studies have highlighted the broad utility of P2Y11 antagonists in immunology and autoimmune disease models (see atomic evidence for GPCR pathway targeting), yet none have demonstrated the direct reversal of QPRT-induced invasiveness as achieved with NF 340 in breast cancer cell models (source: paper).

Furthermore, while prior content such as decoding P2Y11 antagonism in purinergic signaling links NF 340 to breast cancer, this article uniquely analyzes the metabolic signaling axis (QPRT–NAD⁺–P2Y11–myosin light chain) and its practical consequences for experimental design. This deeper mechanistic context allows researchers to hypothesize and test novel intervention points within the inflammation-cancer continuum.

Why This Cross-Domain Matters, Maturity, and Limitations

The clinical implications of modulating purinergic signaling via P2Y11 are profound, especially given the emerging recognition of NAD⁺ metabolism as a hallmark of cancer aggressiveness. However, it is important to note that all current findings are based on in vitro or preclinical models. NF 340, as supplied by APExBIO, is for research use only and is not suitable for therapeutic or diagnostic applications (product_spec). Further validation in patient-derived models and in vivo systems is needed before clinical translation can be contemplated (workflow_recommendation).

Conclusion and Future Outlook

NF 340 stands as a highly selective tool for interrogating the P2Y11-mediated arm of purinergic receptor signaling, offering granularity that is essential for advanced immunology research and mechanistic cancer studies. The reversal of QPRT-driven invasiveness by NF 340, as shown in recent research (Liu et al., 2021), provides a robust paradigm for future investigations into how metabolic and signaling networks converge in disease progression. Researchers seeking to build upon standard cell signaling or inflammation models should consider integrating NF 340 into their experimental workflows to access these deeper biological insights.

For those interested in scenario-driven troubleshooting or atomic-level pathway mapping, see Enhancing Cell Signaling Research and P2Y11 Antagonist B7508: Atomic Evidence for GPCR Pathway. However, the translational perspective offered here—linking metabolic reprogramming to purinergic signaling and cytoskeletal control—is unique in its depth and practical orientation.

To learn more or to source this compound for your research, visit the official NF 340 product page at APExBIO.